What is the share price of Kopran Ltd (KOPRAN) today?
The share price of KOPRAN as on 25th April 2025 is ₹192.15. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kopran Ltd (KOPRAN) share?
The past returns of Kopran Ltd (KOPRAN) share are- Past 1 week: -4.23%
- Past 1 month: 0.94%
- Past 3 months: -0.11%
- Past 6 months: -28.33%
- Past 1 year: -24.30%
- Past 3 years: -29.52%
- Past 5 years: 601.45%
What are the peers or stocks similar to Kopran Ltd (KOPRAN)?
The peers or stocks similar to Kopran Ltd (KOPRAN) include:What is the dividend yield % of Kopran Ltd (KOPRAN) share?
The current dividend yield of Kopran Ltd (KOPRAN) is 1.51.What is the market cap of Kopran Ltd (KOPRAN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kopran Ltd (KOPRAN) is ₹960.21 Cr as of 25th April 2025.What is the 52 week high and low of Kopran Ltd (KOPRAN) share?
The 52-week high of Kopran Ltd (KOPRAN) is ₹369.70 and the 52-week low is ₹155.What is the PE and PB ratio of Kopran Ltd (KOPRAN) stock?
The P/E (price-to-earnings) ratio of Kopran Ltd (KOPRAN) is 18.85. The P/B (price-to-book) ratio is 1.95.Which sector does Kopran Ltd (KOPRAN) belong to?
Kopran Ltd (KOPRAN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kopran Ltd (KOPRAN) shares?
You can directly buy Kopran Ltd (KOPRAN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kopran Ltd
KOPRAN Share Price
192.153.37% (-6.71)
KOPRAN Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
KOPRAN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 20.21 | 1.95 | 1.51% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.69 | 6.47 | 0.52% |
KOPRAN Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KOPRAN Company Profile
Kopran Limited is engaged in pharmaceutical business. The Company's business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.
Investor Presentation
View olderKOPRAN Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
45.20
1Y Return
21.41%
Buy Reco %
88.24
CIPLA
PE Ratio
30.41
1Y Return
10.98%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
67.94
1Y Return
23.77%
Buy Reco %
68.00
MANKIND
PE Ratio
56.06
1Y Return
8.38%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.91
1Y Return
0.87%
Buy Reco %
46.67
KOPRAN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
KOPRAN Stock Summary · November 2024
Kopran Limited is grappling with significant pricing pressures in its Active Pharmaceutical Ingredients (API) segment, particularly from Chinese competitors, which has led to a decline in turnover and a downward revision of EBITDA guidance. Despite these challenges, the formulations business has shown resilience, and management remains cautiously optimistic about achieving revenue growth targets for FY '25, bolstered by new product developments and strategic market expansions in Latin America and the Middle East. The company is also focused on enhancing operational capabilities, with the Panoli plant expected to contribute significantly to revenue by FY '26, while navigating supply chain disruptions exacerbated by the ongoing Red Sea crisis. Additionally, the partnership with Teva is progressing, albeit slower than anticipated due to external factors, highlighting the complex landscape in which Kopran operates.
Key Points on Kopran Stock
KOPRAN Stock Growth Drivers
5Positive Achievements in Financial Performance
Kopran Limited reported a turnover of INR 73.52 crores in its formulations business for Q2
Product Development and R&D Progress
The company has commenced trial production at its Panoli plant, with expectations to start commercial
KOPRAN Stock Challenges
5Decline in API Segment Performance
The active pharmaceutical ingredients (API) segment reported a turnover of INR 78.03 crores for Q2
Revised EBITDA Guidance
The company has adjusted its EBITDA guidance for FY '25 from an initial estimate of
KOPRAN Forecasts
Price
Revenue
Earnings
KOPRAN Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeKOPRAN Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeKOPRAN Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeKOPRAN
Income
Balance Sheet
Cash Flow
Annual Normal View
KOPRAN Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 298.71 | 320.50 | 322.92 | 360.96 | 360.13 | 509.80 | 488.12 | 554.06 | 629.20 | 656.78 | ||||||||||
Raw Materials | 181.44 | 180.85 | 193.05 | 217.24 | 232.83 | 286.27 | 300.57 | 345.95 | 400.88 | 568.88 | ||||||||||
| Power & Fuel Cost | 14.10 | 13.71 | 14.90 | 17.10 | 18.08 | 16.65 | 19.27 | 23.16 | 24.52 | |||||||||||
| Employee Cost | 28.02 | 31.37 | 32.24 | 37.11 | 36.85 | 37.16 | 43.27 | 49.95 | 52.28 | |||||||||||
| Selling & Administrative Expenses | 25.03 | 25.39 | 28.17 | 27.88 | 29.60 | 34.24 | 35.75 | 35.37 | 37.00 | |||||||||||
| Operating & Other expenses | 18.71 | 22.39 | 14.56 | 12.24 | -4.00 | 35.71 | -8.73 | 44.77 | 25.50 | |||||||||||
EBITDA | 31.41 | 46.79 | 40.00 | 49.39 | 46.77 | 99.77 | 97.99 | 54.86 | 89.02 | 87.90 | ||||||||||
| Depreciation/Amortization | 8.12 | 8.33 | 8.51 | 8.74 | 9.58 | 10.19 | 11.10 | 12.71 | 12.89 | 15.31 | ||||||||||
| PBIT | 23.29 | 38.46 | 31.49 | 40.65 | 37.19 | 89.58 | 86.89 | 42.15 | 76.13 | 72.59 | ||||||||||
| Interest & Other Items | 12.56 | 13.70 | 8.60 | 8.99 | 8.91 | 6.24 | 5.12 | 6.08 | 8.59 | 9.16 | ||||||||||
| PBT | 10.73 | 24.76 | 22.89 | 31.66 | 28.28 | 83.34 | 81.77 | 36.07 | 67.54 | 63.43 | ||||||||||
| Taxes & Other Items | 0.00 | 4.85 | 2.40 | 7.64 | 7.27 | 21.73 | 20.75 | 8.83 | 16.59 | 15.91 | ||||||||||
| Net Income | 10.73 | 19.91 | 20.49 | 24.02 | 21.01 | 61.61 | 61.02 | 27.24 | 50.95 | 47.52 | ||||||||||
| EPS | 2.54 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 13.34 | 5.65 | 10.57 | 9.86 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.22 | 0.53 | 0.28 | 0.30 |
KOPRAN Company Updates
FY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFFY 2025
Investor Presentation
Feb 11PDF
KOPRAN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kopran Ltd | 18.85 | 1.95 | 1.51% |
| Sun Pharmaceutical Industries Ltd | 45.20 | 6.45 | 0.75% |
| Cipla Ltd | 30.41 | 4.68 | 0.84% |
| Torrent Pharmaceuticals Ltd | 67.94 | 16.41 | 0.84% |
KOPRAN Stock Price Comparison
Compare KOPRAN with any stock or ETFCompare KOPRAN with any stock or ETF
KOPRAN
KOPRAN Shareholdings
KOPRAN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KOPRAN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KOPRAN Shareholding Pattern
KOPRAN Shareholding History
Foreign Institutions
Mutual Funds Invested in KOPRAN
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Kopran Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0007% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 98/110 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing KOPRAN stock
Looks like this stock is not in any smallcase yet.
KOPRAN Events
KOPRAN Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KOPRAN Upcoming Dividends
No upcoming dividends are available
KOPRAN Past Dividends
Cash Dividend
Ex DateEx DateSep 2, 2024
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 2, 2024
Cash Dividend
Ex DateEx DateSep 7, 2023
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 7, 2023
Cash Dividend
Ex DateEx DateAug 4, 2022
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 4, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateNov 5, 2020
Interim
Interim | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Nov 5, 2020
KOPRAN Stock News & Opinions
Articles & Videos
Earnings
Kopran consolidated net profit declines 34.14% in the December 2024 quarter
Net profit of Kopran declined 34.14% to Rs 10.40 crore in the quarter ended December 2024 as against Rs 15.79 crore during the previous quarter ended December 2023. Sales rose 4.61% to Rs 166.24 crore in the quarter ended December 2024 as against Rs 158.92 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales166.24158.92 5 OPM %11.9314.84 - PBDT17.8623.77 -25 PBT13.8620.51 -32 NP10.4015.79 -34 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Kopran to declare Quarterly Results
Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Kopran allots 36,200 equity shares under ESOP
Kopran has allotted 36,200 equity shares under ESOP on 21 January 2025. With this allotment, the paid up equity share capital has increased to 4,82,85,605 equity shares of Rs. 10/- each aggregating to Rs. 48,28,56,050/-Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Kopran consolidated net profit declines 46.41% in the September 2024 quarter
Net profit of Kopran declined 46.41% to Rs 7.38 crore in the quarter ended September 2024 as against Rs 13.77 crore during the previous quarter ended September 2023. Sales declined 0.68% to Rs 151.56 crore in the quarter ended September 2024 as against Rs 152.59 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales151.56152.59 -1 OPM %9.7214.96 - PBDT13.5021.02 -36 PBT9.6418.25 -47 NP7.3813.77 -46 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Kopran to discuss results
Kopran will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Kopran schedules AGM
Kopran announced that the Annual General Meeting (AGM) of the company will be held on 11 September 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Kopran consolidated net profit rises 300.72% in the June 2024 quarter
Net profit of Kopran rose 300.72% to Rs 11.10 crore in the quarter ended June 2024 as against Rs 2.77 crore during the previous quarter ended June 2023. Sales rose 19.18% to Rs 139.44 crore in the quarter ended June 2024 as against Rs 117.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales139.44117.00 19 OPM %13.025.39 - PBDT18.616.87 171 PBT14.733.61 308 NP11.102.77 301 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Kopran receives environmental clearance for GoI for manufacturing of APIs at Panoli unit
Kopran has received Environmental Clearance from Government of India ' Ministry of Environment, Forest and Climate Change on 30 July 2024 for manufacturing of synthetic organic chemicals (Active Pharmaceutical Ingredients and its Intermediates) up to 97 MTs/Month at its Manufacturing Unit at Plot no. 663, GIDC Panoli, Taluka: Ankleshwar, District: Bharuch, Gujarat. The Company will now obtain Consent to Establish (CTE) and Consent to Operate (CCA) from Gujarat Pollution Control Board for additional capacities approval under the Environmental Clearance received.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Kopran schedules board meeting
Kopran will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Stock market update: Stocks that hit 52-week highs on NSE in today’s trade
1 year agoEconomic Times
Over the last 5 years, revenue has grown at a yearly rate of 11.75%, vs industry avg of 9.04%
Over the last 5 years, market share stayed at 0.16%
Over the last 5 years, net income has grown at a yearly rate of 16.23%, vs industry avg of 15.28%